Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Alijotas-Reig, J; Esteve-Valverde, E; Ferrer-Oliveras, R; Sáez-Comet, L; Lefkou, E; Mekinian, A; Belizna, C; Ruffatti, A; Tincani, A; Marozio, L; Espinosa, G; Cervera, R; Ríos-Garcés, R; De Carolis, S; Latino, O; LLurba, E; Chighizola, CB; Gerosa, M; Pengo, V; Lundelin, K; Rovere-Querini, P; Canti, V; Mayer-Pickel, K; Reshetnyak, T; Hoxha, A; Tabacco, S; Stojanovich, L; Gogou, V; Varoudis, A; Arnau, A; Ruiz-Hidalgo, D; Trapé, J; Sos, L; Stoppani, C; Martí-Cañamares, A; Farran-Codina, I; EUROAPS Study Group.
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.
Autoimmun Rev. 2019; 18(4):406-414
Doi: 10.1016/j.autrev.2018.12.006
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Mayer-Pickel Karoline Ilse
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS). The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%). In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients. Copyright © 2019 Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Abortion, Habitual - drug therapy
- Abortion, Habitual - epidemiology
- Abortion, Habitual - etiology
- Adult -
- Antibodies, Antiphospholipid - immunology
- Antiphospholipid Syndrome - complications
- Antiphospholipid Syndrome - drug therapy
- Antiphospholipid Syndrome - epidemiology
- Antiphospholipid Syndrome - immunology
- Aspirin - therapeutic use
- Cohort Studies -
- Cohort Studies - epidemiology
- Female -
- Follow-Up Studies -
- Heparin, Low-Molecular-Weight - therapeutic use
- Humans -
- Infant, Newborn -
- Pregnancy -
- Pregnancy Complications - drug therapy
- Pregnancy Complications - epidemiology
- Pregnancy Complications - immunology
- Pregnancy Outcome -
- Registries -
- Retrospective Studies -
- Young Adult -
- Find related publications in this database (Keywords)
- Antiphospholipid antibody
- Antiphospholipid syndrome
- Obstetric antiphospholipid syndrome
- Registry
- Pregnancy autoimmune disorders